|
US5288931A
(en)
*
|
1991-12-06 |
1994-02-22 |
Genentech, Inc. |
Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
|
|
US6177078B1
(en)
|
1995-12-29 |
2001-01-23 |
Medvet Science Pty Limited |
Monoclonal antibody antagonists to IL-3
|
|
US7435549B1
(en)
|
1997-11-17 |
2008-10-14 |
Micromet Ag |
Method of identifying binding site domains that retain the capacity of binding to an epitope
|
|
JP2002541061A
(ja)
|
1999-02-08 |
2002-12-03 |
メドベット・サイエンス・プロプライエタリー・リミテッド |
サイトカイン結合ドメイン
|
|
EP1161453A4
(en)
|
1999-02-08 |
2005-01-05 |
Medvet Science Pty Ltd |
CYTOKIN-BINDING DOMAIN
|
|
GB9912350D0
(en)
*
|
1999-05-26 |
1999-07-28 |
European Molecular Biology Lab Embl |
Modified cytokine
|
|
ATE510855T1
(de)
|
2000-03-06 |
2011-06-15 |
Univ Kentucky Res Found |
Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen
|
|
FI117667B
(fi)
*
|
2001-07-05 |
2007-01-15 |
Univ Zuerich |
Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
|
|
NZ543202A
(en)
|
2003-05-31 |
2008-04-30 |
Micromet Ag |
Pharmaceutical composition comprising a bispecific antibody for epcam
|
|
FR2879605B1
(fr)
|
2004-12-16 |
2008-10-17 |
Centre Nat Rech Scient Cnrse |
Production de formats d'anticorps et applications immunologiques de ces formats
|
|
JP2011505386A
(ja)
|
2007-12-06 |
2011-02-24 |
シーエスエル、リミテッド |
白血病性幹細胞の阻害方法
|
|
PE20150680A1
(es)
*
|
2008-11-26 |
2015-05-16 |
Amgen Inc |
Variantes de polipeptidos receptores de activina iib y aplicaciones de estos
|
|
US20100209341A1
(en)
|
2009-02-18 |
2010-08-19 |
Csl Limited |
Treatment of chronic inflammatory conditions
|
|
ES2550639T3
(es)
|
2009-04-27 |
2015-11-11 |
Kyowa Hakko Kirin Co., Ltd. |
Anticuerpo anti-IL-3Ralfa para su utilización en el tratamiento de un tumor de la sangre
|
|
EP2436397B1
(en)
|
2009-05-29 |
2017-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition containing antagonist of egf family ligand as component
|
|
AU2011217728B2
(en)
|
2010-02-17 |
2013-03-14 |
Csl Limited |
Compositions and methods for targeting type 1 interferon producing cells
|
|
BR112012031189B1
(pt)
|
2010-06-07 |
2021-10-26 |
Stepan Company |
Composição, composição biocida diluível e método de limpeza de uma superfície dura
|
|
NZ604510A
(en)
|
2010-08-17 |
2013-10-25 |
Csl Ltd |
Dilutable biocidal compositions and methods of use
|
|
US20130210860A1
(en)
|
2010-10-06 |
2013-08-15 |
Kowa Co., Ltd. |
Prophylactic and/or therapeutic agent against lymphedema
|
|
WO2012059857A2
(en)
|
2010-11-01 |
2012-05-10 |
Symphogen A/S |
Pan-her antibody composition
|
|
US9155802B2
(en)
|
2010-11-01 |
2015-10-13 |
Symphogen A/S |
Pan-HER antibody composition
|
|
US9598499B2
(en)
|
2010-12-30 |
2017-03-21 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Antigen binding formats for use in therapeutic treatments or diagnostic assays
|
|
WO2012106615A1
(en)
*
|
2011-02-03 |
2012-08-09 |
Xoma Technology Ltd. |
Methods and materials for enhancing functional protein expression in bacteria
|
|
GB201203051D0
(en)
*
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
US20160046718A1
(en)
|
2013-03-14 |
2016-02-18 |
Csl Limited |
Agents that neutralize il-3 signalling and uses thereof
|
|
WO2014138805A1
(en)
|
2013-03-14 |
2014-09-18 |
Csl Limited |
Anti il-3r alpha agents and uses thereof
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
TR201910814T4
(tr)
|
2014-03-19 |
2019-08-21 |
Cellectis |
Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri.
|
|
US11041021B2
(en)
*
|
2014-05-23 |
2021-06-22 |
University Of Florida Research Foundation, Incorporated |
Car based immunotherapy
|
|
LT3148579T
(lt)
|
2014-05-28 |
2021-05-25 |
Agenus Inc. |
Anti-gitr antikūnai ir jų panaudojimo būdai
|
|
EP3158064A1
(en)
|
2014-06-17 |
2017-04-26 |
Cellectis |
Cd123 specific multi-chain chimeric antigen receptor
|
|
AU2015279321B2
(en)
|
2014-06-27 |
2021-03-04 |
Innate Pharma, S.A. |
Multispecific antigen binding proteins
|
|
JP6822849B2
(ja)
|
2014-06-27 |
2021-01-27 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
多重特異的NKp46結合タンパク質
|
|
CN105367657B
(zh)
|
2014-08-14 |
2019-09-13 |
上海生物制品研究所有限责任公司 |
抗her3抗体、其制法及其应用
|
|
ES2688035T3
(es)
|
2014-08-29 |
2018-10-30 |
Gemoab Monoclonals Gmbh |
Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
|
|
DK3189081T3
(da)
|
2014-09-05 |
2020-05-04 |
Janssen Pharmaceutica Nv |
Cd123-bindende midler og anvendelser deraf
|
|
MX2017006167A
(es)
|
2014-11-12 |
2018-03-23 |
Siamab Therapeutics Inc |
Compuestos que interactúan con glicanos y métodos de uso.
|
|
AR103488A1
(es)
|
2015-01-23 |
2017-05-10 |
Sanofi Sa |
Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
|
|
EP3250602A1
(en)
|
2015-01-26 |
2017-12-06 |
Cellectis |
T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
|
|
TWI787796B
(zh)
|
2015-05-04 |
2022-12-21 |
美商Cytomx生物製藥公司 |
抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
|
|
TW201709932A
(zh)
|
2015-06-12 |
2017-03-16 |
西雅圖遺傳學公司 |
Cd123抗體及其共軛物
|
|
CA2990398A1
(en)
|
2015-06-23 |
2016-12-29 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-cd123-antibodies
|
|
JP6840682B2
(ja)
|
2015-06-23 |
2021-03-10 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
多重特異的抗原結合タンパク質
|
|
AU2016284871B2
(en)
|
2015-06-23 |
2022-09-29 |
Innate Pharma |
Multispecific NK engager proteins
|
|
CA2994746A1
(en)
|
2015-08-11 |
2017-02-16 |
Cellectis |
Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
|
|
CA3002097A1
(en)
|
2015-11-12 |
2017-05-18 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
WO2017096276A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Anti-gitr antibodies and methods of use thereof
|
|
AU2016364895A1
(en)
|
2015-12-02 |
2018-06-07 |
Agenus Inc. |
Anti-GITR antibodies and methods of use thereof
|
|
MA43389A
(fr)
|
2015-12-02 |
2021-05-12 |
Agenus Inc |
Anticorps anti-ox40 et leurs procédés d'utilisation
|
|
WO2017096179A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
CA3007898A1
(en)
|
2015-12-28 |
2017-07-06 |
Innate Pharma |
Variable regions for nkp46 binding proteins
|
|
WO2017160954A1
(en)
|
2016-03-15 |
2017-09-21 |
Seattle Genetics, Inc. |
Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
|
|
WO2017214433A1
(en)
|
2016-06-09 |
2017-12-14 |
Seattle Genetics, Inc. |
Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
|
|
TWI790206B
(zh)
*
|
2016-07-18 |
2023-01-21 |
法商賽諾菲公司 |
特異性結合至cd3和cd123的雙特異性抗體樣結合蛋白
|
|
EP3713959A1
(en)
|
2017-11-21 |
2020-09-30 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
KR20210133261A
(ko)
|
2019-02-26 |
2021-11-05 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Bcma에 결합하는 항원 결합 단백질
|
|
KR20250152662A
(ko)
*
|
2020-12-31 |
2025-10-23 |
사노피 |
NKp46 및 CD123에 결합하는 다기능성 자연살해(NK) 세포 관여자
|
|
CN117321087A
(zh)
|
2021-03-26 |
2023-12-29 |
先天制药公司 |
包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
|
|
CN117616050A
(zh)
|
2021-06-09 |
2024-02-27 |
先天制药公司 |
与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
|